Search results for "gene therapy."

showing 10 items of 51 documents

SOLID LIPID NANOPARTICLES FOR APPLICATIONS IN GENE THERAPY: A REVIEW OF THE STATE OF THE ART

2010

Importance of the field. Gene therapy represents a new paradigm in the prevention and treatment of many inherited and acquired diseases, including genetic disorders, such as cystic fibrosis, haemophilia and many somatic diseases, such as tumours, neurodegenerative diseases and viral infections, such as AIDS. Areas covered in this review. Among a large array of non-viral transfection agents used for in-vitro applications, cationic SLNs are the topic of this review, being recently proposed as an alternative carrier for DNA delivery, due to many technological advantages such as large-scale production from substances generally recognized as safe, good storage stability and possibility of steam …

Acquired diseasesGenetic enhancementGenetic VectorsPharmaceutical ScienceGene deliveryBiologyBioinformaticsCystic fibrosisGenetic therapyGENE THERAPY SOLID LIPID NANOPARTICLESSolid lipid nanoparticlemedicinegene deliverybusiness.industrynon-viral vectors Read More: http://informahealthcare.com/doi/abs/10.1517/17425240903362410DNAGenetic Therapymedicine.diseasegene therapyLipidsBiotechnologySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMicroscopy Electron ScanningNanoparticlesbusinesscationic solid lipid nanoparticles
researchProduct

Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gam…

2007

Contains fulltext : 52707.pdf (Publisher’s version ) (Closed access) Granulysin is a recently identified cytolytic protein which is expressed by human cytotoxic T-lymphocytes and natural killer (NK)-cells, and has broad antimicrobial and tumoricidal activity. Circulating granulysin levels are associated with T- and NK-cell activity, and may thus reflect protection-associated cellular immune responses. In a case-control study in Indonesia, a highly tuberculosis (TB)-endemic country, we therefore determined plasma granulysin levels in adults with active pulmonary TB before, during, and after TB treatment, both in mild/moderate-TB and advanced-TB patients, and compared these to healthy neighbo…

AdultAntigens Differentiation T-LymphocyteMaleMicrobiology (medical)TuberculosisAdolescentInfectious diseases and international health [NCEBP 13]TuberculosiImmunologyEnzyme-Linked Immunosorbent AssayBiologySeverity of Illness IndexMicrobiologyInterferon-gammaImmune systemAntigenImmunitymedicineHumansCytotoxic T cellInterferon gammaPlasma granulysinCellular granulysinCellular IFN-gGranulysinDisease severityTuberculosis PulmonaryAgedImmunity CellularInterferon-gamma productionPoverty-related infectious diseases [N4i 3]Immunotherapy gene therapy and transplantation [UMCN 1.4]Middle Agedmedicine.diseasePathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCase-Control StudiesPlasma IFN-gImmunologyFemaleMicrobial pathogenesis and host defense [UMCN 4.1]medicine.drugImmunity infection and tissue repair [NCMLS 1]
researchProduct

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

2004

Contains fulltext : 57114.pdf (Publisher’s version ) (Closed access) Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on >90% of renal cell carcinoma (RCC). A multicentre phase II study was performed to evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients. In all, 36 patients with mRCC were included. WX-G250 was given weekly by intravenous infusion for 12 weeks. Patients with stable disease (SD) or response were eligible to receive additional treatment for 8 weeks. None of the 36 enrolled patients experienced any drug-related grade III or IV toxicity. Only three patients had grade II toxicity possibly related to the study medication.…

AdultMaleCancer Researchmedicine.medical_specialtyrenal cell carcinomaRecombinant Fusion ProteinsPhases of clinical researchAntineoplastic AgentsGastroenterologyClinicalMonoclonal antibody G250Renal cell carcinomaInternal medicinemedicineCarcinomaHumansProspective StudiesCarcinoma Renal CellAgedbusiness.industryGirentuximabAntibodies MonoclonalImmunotherapy gene therapy and transplantation [UMCN 1.4]CA-IXMiddle Agedmedicine.diseaseKidney NeoplasmsSurgeryClinical trialTreatment OutcomeOncologymonoclonal antibodyAntigens SurfaceFemaleimmunotherapybusinessWX-G250Progressive diseasemedicine.drugKidney disease
researchProduct

Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of…

2015

Ischemic heart disease remains the leading cause of death worldwide. Ischemic pre-, post-, and remote conditionings trigger endogenous cardioprotection that renders the heart resistant to ischemic-reperfusion injury (IRI). Mimicking endogenous cardioprotection by modulating genes involved in cardioprotective signal transduction provides an opportunity to reproduce endogenous cardioprotection with better possibilities of translation into the clinical setting. Genes and signaling pathways by which conditioning maneuvers exert their effects on the heart are partially understood. This is due to the targeted approach that allowed identifying one or a few genes associated with IRI and cardioprote…

CardiotoxinIschemic heart diseaseCardiologyMyocardial IschemiaPreconditioningMyocardial Reperfusion InjuryCardioprotectionRemote conditioningCardiotoxinsPostconditioningGene therapyMedicalHumansMyocardialIschemic PreconditioningSocieties MedicalCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioning; Cardiology; Cardiotoxicity; Cardiotoxins; Gene Targeting; Genetic Therapy; Humans; Ischemic Preconditioning Myocardial; Italy; Myocardial Ischemia; Myocardial Reperfusion Injury; Oxidative Stress; Societies MedicalCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioning; Cardiology; Cardiotoxicity; Cardiotoxins; Gene Targeting; Genetic Therapy; Humans; Ischemic Preconditioning; Myocardial; Italy; Myocardial Ischemia; Myocardial Reperfusion Injury; Oxidative Stress; Societies; Medical; Cardiology and Cardiovascular MedicineOxidative StreGenomicsGenetic TherapyCardioprotection Gene therapy Genomics Ischemic heart disease Postconditioning Preconditioning Remote conditioningCardiotoxicityOxidative StressCardioprotection; Gene therapy; Genomics; Ischemic heart disease; Postconditioning; Preconditioning; Remote conditioningItalyIschemic Preconditioning MyocardialGene TargetingGenomicSocietiesCardiology and Cardiovascular MedicineHuman
researchProduct

AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity.

2010

The CB1 cannabinoid receptor is the most abundant G-protein coupled receptor in the brain and a key regulator of neuronal excitability. There is strong evidence that CB1 receptor on glutamatergic hippocampal neurons is beneficial to alleviate epileptiform seizures in mouse and man. Therefore, we hypothesized that experimentally increased CB1 gene dosage in principal neurons would have therapeutic effects in kainic acid (KA)-induced hippocampal pathogenesis. Here, we show that virus-mediated conditional overexpression of CB1 receptor in pyramidal and mossy cells of the hippocampus is neuroprotective and moderates convulsions in the acute KA seizure model in mice. We introduce a recombinant a…

Central Nervous SystemCannabinoid receptormedicine.medical_treatmentHippocampuslcsh:MedicineHippocampal formationHippocampuschemistry.chemical_compoundMiceReceptor Cannabinoid CB1Neurobiology of Disease and RegenerationTransgeneslcsh:ScienceNeuronsRecombination GeneticMultidisciplinaryBehavior AnimalNeuromodulationmusculoskeletal neural and ocular physiologyfood and beveragesNeurochemistryGenomicsGene TherapyDependovirusEndocannabinoid systemCell biologyFunctional GenomicsNeurologyHomeostatic MechanismsMedicinelipids (amino acids peptides and proteins)Viral VectorsNeurochemicalsGenetic EngineeringResearch ArticleBiotechnologyKainic acidGenetic VectorsGreen Fluorescent ProteinsNeurophysiologyBiologyMicrobiologyVector BiologyGlutamatergicGenomic MedicineSeizuresmedicineGeneticsAnimalsBiologyEpilepsyIntegrasesDentate gyruslcsh:RMolecular biologyMice Inbred C57BLchemistryGene Expression Regulationnervous systemGenetics of DiseaseSynapseslcsh:QCannabinoidGene FunctionMolecular NeuroscienceAnimal GeneticsTransgenicsNeuroscienceEndocannabinoidsPLoS ONE
researchProduct

Baculovirus capsid display: a novel tool for transduction imaging

2003

Baculoviruses are enveloped insect viruses that can carry large quantities of foreign DNA in their genome. Baculoviruses have proved to be very promising gene therapy vectors but little is known about their transduction mechanisms in mammalian cells. We show in this study that Autographa californica multiple nuclear polyhedrosis virus capsid is compatible with the incorporation of desired proteins in large quantities. Fusions can be made to the N-terminus or C-terminus of the major capsid protein vp39 without compromising the viral titer or functionality. As an example of the baculovirus capsid display we show a tracking of the baculovirus transduction in mammalian cells by an enhanced gree…

CytoplasmTime FactorsvirusesGenetic VectorsGreen Fluorescent ProteinsImmunoblottingVectors in gene therapyVirusGreen fluorescent proteinCell LineTransduction (genetics)Viral ProteinsProtein structureCapsidDrug DiscoveryGeneticsAnimalsHumansTransgenesMolecular BiologyPharmacologyMicroscopy ConfocalbiologyfungiNuclear Polyhedrosis VirusBrainbiology.organism_classificationCell biologyProtein Structure TertiaryRatsAutographa californicaLuminescent ProteinsMicroscopy ElectronCapsidGenetic TechniquesMolecular MedicineCapsid ProteinsPeptidesBaculoviridaePlasmidsMolecular Therapy
researchProduct

Comparative Antitumor Effect of Preventive versus Therapeutic Vaccines Employing B16 Melanoma Cells Genetically Modified to Express GM-CSF and B7.2 i…

2012

Cancer vaccines have always been a subject of gene therapy research. One of the most successful approaches has been working with genetically modified tumor cells. In this study, we describe our approach to achieving an immune response against a murine melanoma model, employing B16 tumor cells expressing GM-CSF and B7.2. Wild B16 cells were injected in C57BL6 mice to cause the tumor. Irradiated B16 cells transfected with GM-CSF, B7.2, or both, were processed as a preventive and therapeutic vaccination. Tumor volumes were measured and survival curves were obtained. Blood samples were taken from mice, and IgGs of each treatment group were also measured. The regulatory T cells (Treg) o…

Cytotoxicity Immunologicnon-viralHealth Toxicology and MutagenesisGenetic enhancementMelanoma Experimentallcsh:MedicineToxicologyTransfectionT-Lymphocytes RegulatoryImmunoglobulin GArticleMiceImmune systemCell Line TumormedicineAnimalsbiologylcsh:RGene Transfer TechniquesCancerGranulocyte-Macrophage Colony-Stimulating FactorGM-CSFTransfectionGenetic Therapymedicine.diseaseSurvival Analysisgene therapyGenetically modified organismVaccinationMice Inbred C57BLGranulocyte macrophage colony-stimulating factorB7.2Immunoglobulin GImmunologybiology.proteinB7-2 AntigenNeoplasm Transplantationcancer vaccinesmedicine.drugToxins
researchProduct

Gene therapy for type 1 diabetes: is it ready for the clinic?

1999

This review, in addition to updating the growing list of type 1 diabetes- relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.

Diabetes; Gene therapy; Immunotherapy; Autoimmunity.medicine.medical_treatmentGenetic enhancementTransgeneImmunologyGenetic VectorsAutoimmunity.BioinformaticsDiabeteAdenoviridaeGene therapyAntigenmedicineAnimalsHumansProgenitor cellgeographyType 1 diabetesgeography.geographical_feature_categorybusiness.industryInsulinGene Transfer TechniquesImmunosuppressionGenetic TherapyIsletmedicine.diseaseDiabetes Mellitus Type 1Immunotherapybusiness
researchProduct

Current strategies to improve the efficacy and the delivery of nucleic acid based drugs

2010

EndocrinologyChemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNucleic acid based drugs drug delivery gene therapyNABD deliveryNucleic acidPharmacology (medical)Computational biologyCurrent (fluid)
researchProduct

Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far?

2020

Gene therapy is an alternative therapy in many respiratory diseases with genetic origin and currently without curative treatment. After five decades of progress, many different vectors and gene editing tools for genetic engineering are now available. However, we are still a long way from achieving a safe and efficient approach to gene therapy application in clinical practice. Here, we review three of the most common rare respiratory conditions—cystic fibrosis (CF), alpha-1 antitrypsin deficiency (AATD), and primary ciliary dyskinesia (PCD)—alongside attempts to develop genetic treatment for these diseases. Since the 1990s, gene augmentation therapy has been applied in multiple clinical tria…

Genetic enhancementalpha-1-antitrypsin deficitprimary ciliary dyskinesialcsh:MedicineReviewrare respiratory diseasesBioinformaticsViral vectorcystic fibrosis03 medical and health sciences0302 clinical medicineGenome editingMedicineGene030304 developmental biologyPrimary ciliary dyskinesia0303 health sciencesTranscription activator-like effector nucleaseEffectorbusiness.industrylcsh:RGeneral Medicinemedicine.diseasegene therapyClinical trial030220 oncology & carcinogenesisbusinessJournal of Clinical Medicine
researchProduct